NCT02667873
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02667873
Title A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Stemline Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Yale Cancer Center New Haven Connecticut 06520 United States Details
Florida Cancer Specialist Sarasota Florida 34236 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
Mary Crowely Cancer Research Centers- Medical City Dallas Texas 75230 United States Details
University of Texas Southwestern Medical Center Dallas Texas 75390 United States Details
University of Washington, Seattle Cancer Care Alliance Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field